Approximately one year after granting Trodelvy accelerated approval, the Food and Drug Administration granted a regular approval to the antibody-drug conjugate in certain patients with pretreated triple-negative breast cancer.
On social media, CURE® recently asked its readers to share if they have experienced any side effects from cancer treatment and how they have managed them. Here’s what some of them said.
The Food and Drug Administration’s Oncologic Drugs Advisory Committee unanimously voted in favor of waiting for more data before making an approval decision involving the use of Keytruda in early triple-negative breast cancer.
